NeuroMetrix maintains an active R&D program. Our strategy is to develop unique, proprietary medical devices that utilize non-invasive neurostimulation to diagnose and treat neurological conditions and pain. We seek to define new product categories and leapfrog existing technology. We develop products using our specialized in-house 10-person R&D team.



The Quell® technology currently has the following indications:

We are seeking to expand the FDA authorized clinical indications to include a number of chronic pain and neurological conditions with high prevalence and unmet treatment needs.